Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants
| Autor: | Mark Reinwald, Eckhard Thiel, Karin Heufelder, Ulrich Keilholz, J. M. Siehl, Hans D. Menssen |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Gene isoform
Adult Male medicine.medical_specialty RNA Splicing Bone Marrow Cells Biology Drug Delivery Systems Recurrence Internal medicine medicine Humans Protein Isoforms RNA Neoplasm WT1 Proteins Gene Aged Aged 80 and over Hematology Gene Expression Regulation Leukemic Reverse Transcriptase Polymerase Chain Reaction Myeloid leukemia Wilms' tumor Cell Differentiation General Medicine Middle Aged medicine.disease Molecular biology Reverse transcription polymerase chain reaction Leukemia Leukemia Myeloid Acute medicine.anatomical_structure Cancer research Female Bone marrow |
| Zdroj: | Annals of hematology. 83(12) |
| ISSN: | 0939-5555 |
| Popis: | WT1 is a transcription factor involved in differentiation and proliferation of acute myeloid leukemia (AML) blasts and is expressed in 90% of cases, as determined by nested reverse transcription polymerase chain reaction (RT-PCR). It is proposed to be a key molecule in leukemia promotion. To assess the relevance of WT1 expression, we analyzed blood and bone marrow samples from 58 AML patients (37 at diagnosis, 8 in hematological remission, and 13 at relapse) for the level of WT1 expression, using quantitative real-time RT-PCR. In addition, 21 randomly chosen samples were also analyzed for the quantitative expression of the main WT1 splice variants. As expected, samples from patients at the time of diagnosis or relapse showed significantly higher WT1 expression compared to samples from patients in remission or control samples. No striking difference in expression levels was found between various French-American-British (FAB) subtypes. The level of WT1 expression observed in patients at the time of initial diagnosis was similarly high in patients at relapse. Expression of the four main isoforms (E5+/KTS+, E5−/KTS+, E5+/KTS−, and E5−/KTS−) was found in all samples with significantly higher expression levels of the E5+ variants. Together, these findings support the potential of WT1 as a target for novel treatment approaches in AML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink